PW Medtech Group Ltd. (HK:1358)
:1358
Want to see HK:1358 full AI Analyst Report?
Top Page
PW Medtech Group Ltd.
(1358)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$1.00
▼(-23.08% Downside)
Action:DowngradedDate:04/30/26
The score is driven primarily by solid financial foundations (especially very low leverage) but tempered by FY2025 operating deceleration and margin compression, along with less consistent cash flow. Technicals are weaker with the stock trading below major moving averages, while valuation is supported by a high dividend yield and a moderate P/E but carries added risk given the recent profitability slowdown.
Positive Factors
Conservative Balance Sheet
Extremely low leverage provides durable financial flexibility: it lowers refinancing and solvency risk, supports continued R&D/capex funding or dividends during downturns, and gives management capacity to pursue opportunistic M&A or investments without stressing cash flows.
Negative Factors
Recent Revenue Decline
A clear top-line contraction removes momentum behind prior growth and can erode scale benefits. Persisting declines reduce operating leverage, pressure margins and free cash flow, and may require strategic shifts or increased investment to regain market share over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage provides durable financial flexibility: it lowers refinancing and solvency risk, supports continued R&D/capex funding or dividends during downturns, and gives management capacity to pursue opportunistic M&A or investments without stressing cash flows.
Read all positive factors
PW Medtech Group Ltd. (1358) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.65B
Dividend Yield7.46%
Average Volume (3M)1.12M
Price to Earnings (P/E)19.0
Beta (1Y)0.27
Revenue Growth7.11%
EPS Growth-34.66%
CountryHK
Employees1,415
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,473,589,100
10 Day Avg. Volume754,100
30 Day Avg. Volume1,124,400
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.44
Price to Sales (P/S)2.18
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PW Medtech Group Ltd. Business Overview & Revenue Model
Company Description
PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People's Republic of China. The company manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets,...
PW Medtech Group Ltd. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
88
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 802.19M | 768.90M | 675.08M | 536.83M | 271.40M |
| Gross Profit | 396.91M | 419.45M | 380.90M | 298.82M | 166.06M |
| EBITDA | 229.51M | 270.97M | 329.48M | 175.49M | 77.98M |
| Net Income | 91.93M | 150.78M | 153.18M | 106.04M | 739.12M |
Balance Sheet | |||||
| Total Assets | 5.24B | 5.16B | 5.15B | 4.99B | 3.92B |
| Cash, Cash Equivalents and Short-Term Investments | 1.81B | 1.69B | 1.59B | 1.39B | 2.41B |
| Total Debt | 22.01M | 12.07M | 1.13M | 4.24M | 2.44M |
| Total Liabilities | 360.81M | 357.56M | 327.06M | 351.56M | 122.64M |
| Stockholders Equity | 3.95B | 3.97B | 4.04B | 3.95B | 3.79B |
Cash Flow | |||||
| Free Cash Flow | 135.65M | 246.34M | 129.12M | 216.77M | 25.92M |
| Operating Cash Flow | 240.70M | 318.43M | 211.03M | 269.23M | 37.24M |
| Investing Cash Flow | 6.71M | -20.32M | -26.66M | -1.08B | 2.64B |
| Financing Cash Flow | -126.51M | -210.66M | 17.53M | -85.16M | -2.09B |
PW Medtech Group Ltd. Technical Analysis
Neutral
1.30
Price Trends
1.19
Negative
1.25
Negative
1.33
Negative
Market Momentum
>-0.01
Negative
59.96
Neutral
88.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1358, the sentiment is Neutral. The current price of 1.3 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.19, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.96 is Neutral, neither overbought nor oversold. The STOCH value of 88.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1358.
PW Medtech Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$5.74B | 8.36 | 16.76% | 3.65% | 11.07% | 48.01% | |
69 Neutral | HK$8.44B | 20.75 | 11.20% | ― | 25.24% | 7.29% | |
68 Neutral | HK$16.05B | 13.02 | 6.64% | 4.58% | 2.34% | -22.13% | |
67 Neutral | HK$1.65B | 19.04 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$14.95B | ― | 4.03% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1358
PW Medtech Group Ltd.
1.12
0.17
17.89%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.55
-1.92
-35.08%
HK:3600
Modern Dental Group Limited
6.15
2.15
53.87%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
39.98
13.48
50.87%
HK:6699
Angelalign Technology Inc.
87.50
39.49
82.25%
PW Medtech Group Ltd. Corporate Events
PW Medtech Sets 2026 AGM to Approve Dividend, Board Changes and Capital Mandates
Apr 24, 2026
PW Medtech Group Limited has called its 2026 annual general meeting for June 26, 2026, in Beijing, where shareholders will review the audited financial statements for the year ended December 31, 2025, consider a proposed final dividend of HK2.0 ce...
PW Medtech Extends RMB180 Million Loan to Third-Party Borrower by Two Years
Apr 23, 2026
PW Medtech Group Ltd., through an indirect wholly owned subsidiary acting as lender, has extended the maturity of an existing RMB180 million loan provided to an independent third-party borrower, shifting the due date from 23 April 2026 to 23 April...
PW Medtech Grows Revenue but Profit Drops Amid Pricing Pressure
Mar 27, 2026
PW Medtech Group Limited reported 2025 revenue of RMB823.5 million, up 7.1% year on year, driven by steady growth in its blood purification business and the solid commercial rollout of its regenerative medical biomaterials unit, which helped offse...
PW Medtech Declares HKD 0.02 Final Dividend for 2025 Financial Year
Mar 27, 2026
PW Medtech Group Limited has declared a final ordinary cash dividend of HKD 0.02 per share for the financial year ended 31 December 2025, reflecting its decision to return cash to shareholders. The dividend is subject to shareholder approval on 26...
PW Medtech Sets Arm’s-Length Framework for Intra-Group Medical Components Sales
Mar 27, 2026
PW Medtech Group’s subsidiary Beijing Fert has signed a sale of medical components framework agreement with Sichuan Ruijian Medical, covering blood purification consumables and related components for internal group transactions. The framewor...
PW Medtech Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 17, 2026
PW Medtech Group Limited has scheduled a board meeting for 27 March 2026 to review and approve the consolidated annual results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividend, a decision that...
PW Medtech Unit Drops Plan for Beijing Stock Exchange Listing
Mar 12, 2026
PW Medtech Group Limited has announced that its subsidiary Sichuan Ruijian Medical will not proceed with a planned subsequent listing on the Beijing Stock Exchange, revising earlier plans to further list the unit following its successful quotation...
PW Medtech flags sharply lower 2025 profit on China procurement squeeze
Mar 9, 2026
PW Medtech Group Limited has warned that its net profit for 2025 is expected to fall to between RMB120 million and RMB147 million, down 24% to 38% from 2024, with profit attributable to shareholders dropping 32% to 45% to a range of RMB83 million ...
PW Medtech Subsidiary Sichuan Ruijian Medical Posts Double-Digit Revenue and Profit Growth in 2025
Feb 12, 2026
Non-wholly owned subsidiary Sichuan Ruijian Medical, a blood purification device specialist listed on China’s NEEQ, reported strong audited 2025 results, with revenue rising 27.22% to RMB614.6 million and profit for the year up 14.71% to RMB...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.